Page 5,590«..1020..5,5895,5905,5915,592..5,6005,610..»

MS Awareness Week kicks off

Posted: Published on March 12th, 2013

Multiple Sclerosis Awareness Week will be held March 11-17 with events planned during the week in the greater Rochester area. As part of the effort to raise awareness about MS, Rochester's City Hall will be lit up orange. Mayor Tom Richards joined members of the National MS Upstate Chapter Monday morning to talk about the importance of the initiative. "I have personal friends who have suffered from MS, so I know what it can mean and what it can mean to people who have to live with it," he said. Tisha Sarnowski of East Irondequoit is one of 2,700 people in the greater Rochester area living with MS. She was diagnosed with the disease at 24. "I think I cried atthat point intime and from there it wastreatment options," she said. Multiple scerlosis attacks the central nervous system, interrupting flow of information from the brain to the body. "Being diagnosed early gave me the benefit of having treatment options," said Sarnowski. There is no cure for MS, but Sarnowski says raising awareness about the disease has helped improve her treatments. When she was first diagnosed, Sarnowski received daily injections. Today, she goes for and IV treatment once a month. In … Continue reading →

Posted in MS Treatment | Comments Off on MS Awareness Week kicks off

Speaking of MS – Tue, 12 Mar 2013 PST

Posted: Published on March 12th, 2013

MIKE BONNICKSEN photo Deanna Kirkpatrick shares a laugh with a guest while recording apodcast. (Full-size photo)(All photos) To treat multiple sclerosis, try acupuncture or herbs. Or place your hope in a new oral drug called BG-12. Or one of the other drugs whose ads appear on your browser when you look up MS on WebMD. Or consider restoring your mobility with nutrition. Or snakevenom. While theres no cure for multiple sclerosis, theres no shortage of information and advice online about the disease good, bad and ugly, said Deanna Kirkpatrick, 45, an East Wenatchee woman who helps create three podcasts aboutMS. Shes trying to be the good. She uses the podcasts to pursue answers to her own questions and to those of the thousands of people whove tuned in online since she helped launch Multiple Sclerosis Unplugged just over a year ago. The shows have been heard nearly 30,000 times by people around theworld. The Internet has changed the way people get information about their health and influenced their medical decisions, especially for people with chronic conditions such asMS. Among many studies on the subject, a report released by the Pew Internet & American Life Project in 2007 said 86 percent … Continue reading →

Posted in MS Treatment | Comments Off on Speaking of MS – Tue, 12 Mar 2013 PST

Combination therapy provides similar clinical benefit as single drug treatment in MS

Posted: Published on March 12th, 2013

Public release date: 11-Mar-2013 [ | E-mail | Share ] Contact: Christie Corbett newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue of Annals of Neurology. In the Phase III CombiRx trial, researchers led by Fred Lublin, MD, of The Mount Sinai Medical Center, sought to determine if Glatiramer Acetate (GA) and Interferon Beta-1a (IFN), the two most commonly-prescribed drugs for relapsing-remitting MS (RRMS), were more effective in combination than as monotherapies. The results showed that while combination therapy was no better than monotherapy, patients who took combination therapy had a reduction in new lesions on MRI scan. "This is the first NIH-sponsored, multi-center, comparative trial evaluating the benefits of both combination therapy and monotherapy in MS," said lead author Fred Lublin, MD, Director of the Corinne Goldsmith … Continue reading →

Posted in MS Treatment | Comments Off on Combination therapy provides similar clinical benefit as single drug treatment in MS

Transgender MMA Fighter Wants to Spar with Women in UFC – Video

Posted: Published on March 12th, 2013

Transgender MMA Fighter Wants to Spar with Women in UFC Transgender MMA fighter Fallon Fox demolished her female opponent in 39 seconds in a Championship Fighting Alliance (CFA) bout in Florida. As John Basedow re... By: Buzz60 … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Transgender MMA Fighter Wants to Spar with Women in UFC – Video

Shire Acquires Premacure AB

Posted: Published on March 12th, 2013

Lexington, Massachusetts (ots/PRNewswire) - Deal Enhances Shire's Late-Stage Pipeline with the Acquisition of a Phase II Protein Replacement Therapy Being Investigated for the Prevention of Retinopathy of Prematurity Shire plc announces that it has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in Phase II development, for the prevention of retinopathy of prematurity (ROP). ROP is a rare and potentially blinding eye disorder that primarily affects premature infants and is one of the most common causes of visual loss in childhood. Currently, only symptomatic treatment is available for ROP. Shire will purchase Premacure for an upfront payment and certain contingent payments based on the achievement of pre-specified development and commercial milestones. This acquisition underscores and expands Shire's commitment to bringing innovative therapies to patients with rare disorders worldwide. During normal gestation, the developing fetus is reliant on certain growth factors from the maternal serum; full term babies can produce these growth factors on their own. In preterm infants (born before 31 weeks of gestation), the early separation from the maternal circulation results in a loss of specific growth factors, such as insulin-like growth factor 1 (IGF-1), that are believed to result … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Shire Acquires Premacure AB

Healthy Hollywood: Try It On Tuesday – Stem – Cell Skincare!

Posted: Published on March 12th, 2013

In the quest to be forever young, like Hollywood's ageless beauty Halle Berry, skincare gurus have come up with the most cutting-edge anti-aging ingredient - stem-cells! These renewable cells have been hailed as the medical world's next great hope with the potential to cure everything from Parkinson's to liver disease to a host of other degenerative conditions. Now, the beauty biz is jumping into stem-cell's potential to be an effective skincare ingredient. "In our bodies stem cells work to repair damaged or diseased skin. That's their role - to rejuvenate damaged tissue in our skin, the extracts from human stem cells work to identify skin that has been damaged by age and sun damage, and then repair and rejuvenate wrinkles, skin laxity and the overall complexion," explains New York City dermatologist Dr. Elizabeth K. Hale, who endorses Lifeline a stem-cell skincare line. PLAY IT NOW: Halle Berry: Did Seth MacFarlanes Boob Song Strike A Sour Note With Her? While plant stem-cells have been used in skincare products for the past few years, Lifeline is the first company to use non-embryonic human stem cells. Their product taps into the potency of stem cells to renew skin. While the ethics of stem-cell … Continue reading →

Posted in Stem Cell Research | Comments Off on Healthy Hollywood: Try It On Tuesday – Stem – Cell Skincare!

Stem Cell Therapeutics Announces Filing of Prospectus Supplement for Proceeds Up to $3.5 Million of Units

Posted: Published on March 12th, 2013

TORONTO, ONTARIO--(Marketwire - March 12, 2013) - NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, announced today that it has filed its prospectus supplement dated March 11, 2013 in each of the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia to SCT's base shelf prospectus of March 1, 2011 in respect of its previously announced offering of securities. The offering consists of up to 14,000,000 units ("Units") which will be offered at $0.25 each for gross proceeds of up to $3.5 million. Each Unit will be comprised of one common share and one common share purchase warrants (the "Warrants"). Each Warrant will entitle the holder to purchase an additional common share for $0.40 for a period of 60 months following the closing of the offering. Euro Pacific Canada Inc. is acting as the agent for the offering. Closing of the offering is expected to occur on or about March 15, 2013 and is subject to customary conditions, including the approval of the TSX Venture Exchange. The purpose of the offering is to provide the resources necessary … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell Therapeutics Announces Filing of Prospectus Supplement for Proceeds Up to $3.5 Million of Units

Stem Cell / Regenerative Medicine & HSCT / Cord Blood Market Analysis in New Research Report at ReportsnReports.com

Posted: Published on March 12th, 2013

Cellular Therapy and Cord Blood 2013 Market Report is the new market research report added to the ReportsnReports.com store. Dallas, TX (PRWEB) March 12, 2013 The report analysis clinical trial trends and the evolution of several therapeutics areas within cellular therapy [orthopedic, skin/wound care, cardiovascular, and CNS disorders] and present the current status of every single program within the preclinical through the various clinical trial phases and onto commercialization. The report also presents the breakout of clinical trials in the bonafide cellular therapy sector with respect to geographic breakout, breakout by type of cells utilized, and disease classes interrogated. The report Cellular Therapy and Cord Blood 2013 Market Report also provides a detailed quantitative analysis of the cord blood field as it is rapidly evolving. The report provides hard numbers on sizes of the various registries, the TNC breakouts of banked units, detailed cost breakouts for banking as well as HSCTs utilizing cord blood. Furthermore, the report has been able to compare the EU and US markets side-by-side in this analysis. The report also presents the ATMP regulatory guidelines governing the marketing authorization of cellular therapeutics in the European Union. Details on the statute as well as implications to companies … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell / Regenerative Medicine & HSCT / Cord Blood Market Analysis in New Research Report at ReportsnReports.com

How Well Do You Want to Know Your DNA?

Posted: Published on March 12th, 2013

By: Cat Wise On tonight's PBS NewsHour, Correspondent Spencer Michels and I report on a massive, groundbreaking study underway at Kaiser Permanente and the University of California at San Francisco, which one day may shed light on the genetic roots of health conditions such as Parkinson's, cancer, Alzheimer's and heart disease. UCSF Professor Neil Risch, the lead genetic researcher, told the NewsHour that the information researchers are gathering from genetic studies, at his lab and others, are on the verge of revolutionizing medicine. "We can actually look to see how the genes that somebody has, and they've had since they were born, interact with environmental factors that actually work together to either increase or decrease risk of say heart disease or cancer or a whole variety of things," Risch said. The 200,000 Kaiser Permanente patients who submitted their saliva and blood for genetic analysis will not learn their own genetic profile; the data bank Risch and his colleagues are compiling is for research only. But a number of private companies, including 23andme are now offering personal genetics testing for as little as $99. Despite all the research in recent years, scientists still know very little about how our genes impact … Continue reading →

Comments Off on How Well Do You Want to Know Your DNA?

TiGenix to Obtain National Reimbursement in Spain for Its Innovative Cartilage Therapy ChondroCelect(R)

Posted: Published on March 12th, 2013

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Mar 12, 2013) - TiGenix NV ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect will obtain national reimbursement in Spain. "We are delighted with the decision of the Spanish health authorities to reimburse ChondroCelect, and look forward to working with Spanish orthopedic centers of excellence to routinely make this breakthrough therapy available to the right patients in Spain," said Eduardo Bravo, CEO of TiGenix. "After obtaining national reimbursement in the Netherlands last year, this constitutes another major step in improving patient access to this innovative therapy. We keep working to obtain national reimbursement in other European countries later this year." About TiGenix TiGenix NV ( EURONEXT BRUSSELS : TIG ) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com. About ChondroCelect ChondroCelect is … Continue reading →

Comments Off on TiGenix to Obtain National Reimbursement in Spain for Its Innovative Cartilage Therapy ChondroCelect(R)

Page 5,590«..1020..5,5895,5905,5915,592..5,6005,610..»